KR102495840B1 - PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체 - Google Patents

PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체 Download PDF

Info

Publication number
KR102495840B1
KR102495840B1 KR1020177000523A KR20177000523A KR102495840B1 KR 102495840 B1 KR102495840 B1 KR 102495840B1 KR 1020177000523 A KR1020177000523 A KR 1020177000523A KR 20177000523 A KR20177000523 A KR 20177000523A KR 102495840 B1 KR102495840 B1 KR 102495840B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
reaction
mmol
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177000523A
Other languages
English (en)
Korean (ko)
Other versions
KR20170016465A (ko
Inventor
청더 우
타오 유
슈후이 첸
Original Assignee
치아타이 티안큉 파마수티컬 그룹 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54934872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102495840(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed by 치아타이 티안큉 파마수티컬 그룹 주식회사 filed Critical 치아타이 티안큉 파마수티컬 그룹 주식회사
Publication of KR20170016465A publication Critical patent/KR20170016465A/ko
Application granted granted Critical
Publication of KR102495840B1 publication Critical patent/KR102495840B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020177000523A 2014-06-17 2015-06-16 PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체 Active KR102495840B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410271282.9 2014-06-17
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201510324348 2015-06-12
CN201510324348.0 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物

Publications (2)

Publication Number Publication Date
KR20170016465A KR20170016465A (ko) 2017-02-13
KR102495840B1 true KR102495840B1 (ko) 2023-02-03

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000523A Active KR102495840B1 (ko) 2014-06-17 2015-06-16 PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체

Country Status (11)

Country Link
US (1) US9856256B2 (enExample)
EP (1) EP3159341B8 (enExample)
JP (1) JP6680774B2 (enExample)
KR (1) KR102495840B1 (enExample)
CN (1) CN106470992B (enExample)
AU (1) AU2015276699B2 (enExample)
CA (1) CA2951971C (enExample)
EA (1) EA032642B1 (enExample)
ES (1) ES2754264T3 (enExample)
TW (1) TWI628180B (enExample)
WO (1) WO2015192760A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602815B (zh) * 2015-12-16 2020-07-28 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US12325695B2 (en) * 2019-01-24 2025-06-10 Jiangsu Aosaikang Pharmaceutical Co., Ltd. 5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor
JP7765088B2 (ja) 2019-12-02 2025-11-06 ストーム・セラピューティクス・リミテッド Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物
EP4095137A4 (en) * 2020-02-10 2024-03-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. USE OF A PYRIDO[1,2-A]PYRIMIDINONE COMPOUND FOR THE TREATMENT OF LYMPHOMAS
CN115135649A (zh) * 2020-03-10 2022-09-30 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
CN116323609A (zh) * 2020-09-15 2023-06-23 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途
CN116761608A (zh) * 2020-12-08 2023-09-15 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508290A (ja) 2003-10-10 2007-04-05 ファイザー・プロダクツ・インク ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
JP2009542684A (ja) 2006-06-30 2009-12-03 スネシス ファーマシューティカルズ ピリジノニルｐｄｋ１阻害剤
WO2013071698A1 (zh) 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
MX315904B (es) * 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
CN103096977B (zh) * 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
BR112016029825B1 (pt) * 2014-06-17 2020-10-27 Cisen Pharmaceutical Co., Ltd. composto

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508290A (ja) 2003-10-10 2007-04-05 ファイザー・プロダクツ・インク ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
JP2009542684A (ja) 2006-06-30 2009-12-03 スネシス ファーマシューティカルズ ピリジノニルｐｄｋ１阻害剤
WO2013071698A1 (zh) 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Also Published As

Publication number Publication date
CN106470992B (zh) 2018-11-06
TW201625612A (zh) 2016-07-16
EA032642B1 (ru) 2019-06-28
US20170137420A1 (en) 2017-05-18
CA2951971C (en) 2024-09-10
KR20170016465A (ko) 2017-02-13
EA201790016A1 (ru) 2017-06-30
JP2017519821A (ja) 2017-07-20
CA2951971A1 (en) 2015-12-23
AU2015276699A1 (en) 2017-01-19
EP3159341A4 (en) 2018-05-16
EP3159341A1 (en) 2017-04-26
AU2015276699B2 (en) 2019-10-10
EP3159341B8 (en) 2020-01-08
CN106470992A (zh) 2017-03-01
TWI628180B (zh) 2018-07-01
ES2754264T3 (es) 2020-04-16
EP3159341B1 (en) 2019-08-21
JP6680774B2 (ja) 2020-04-15
US9856256B2 (en) 2018-01-02
WO2015192760A1 (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
KR102495840B1 (ko) PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체
TWI863945B (zh) 2-側氧基喹唑啉衍生物作為甲硫胺酸腺苷基轉移酶２ａ抑制劑
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
JP6577613B2 (ja) キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
AU2014324595B2 (en) Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EP3159342B1 (en) Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
AU2014241152A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
CN105461711B (zh) 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
BRPI0806811A2 (pt) derivados de purina
TW202334167A (zh) 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物
EP4267137A1 (en) Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
CN112912142B (zh) 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物
JP7604067B2 (ja) ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途
JP6900406B2 (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
CN117015528A (zh) 作为激酶抑制剂的吲哚衍生物
TW202110843A (zh) 含氮雜環類衍生物調節劑、其製備方法和應用
HK1238629B (zh) 作为pi3k抑制剂的吡啶并[1，2-a]嘧啶酮类似物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200612

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220120

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220722

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221220

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230131

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230201

End annual number: 3

Start annual number: 1

PG1601 Publication of registration